Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 8/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | WNT1 | P04628 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136240 | 0.86 | CD38 (0.59) | CD38CNR1CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL30363874 | 0.86 | CD38 (0.59) | CD38CNR1CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL29182248 | 0.86 | CD38 (0.59) | CD38CNR1CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25136061 | 0.86 | CD38 (0.46) | CD38GSK3BDYRK1AWNT1CYP2D6 | |
| SCHEMBL25136164 | 0.85 | GSK3B (0.46) | CD38GSK3BDYRK1AWNT1CNR1 | |
| SCHEMBL25136093 | 0.84 | CD38 (0.45) | CD38GSK3BDYRK1AWNT1CYP2D6 | |
| SCHEMBL30363917 | 0.84 | CD38 (0.45) | CD38GSK3BDYRK1AWNT1CYP2D6 | |
| SCHEMBL25136035 | 0.84 | CD38 (0.48) | CD38GSK3BDYRK1AWNT1CYP2D6 | |
| SCHEMBL25136026 | 0.84 | CD38 (0.45) | CD38GSK3BDYRK1AWNT1CYP2D6 | |
| SCHEMBL29182195 | 0.84 | CD38 (0.48) | CD38GSK3BDYRK1AWNT1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885GSK3B 395/4885DYRK1A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.